Brief: Pacira Biosciences Q3 Revenue USD 179.5 Million Vs. IBES Estimate USD 182.9 Million
06/11/2025 21:01
Nov 06 (Reuters) - Pacira Biosciences Q3 adjusted net income USD 31.8 million vs. IBES estimate USD 31.8 million. Q3 net income USD 5.4 million Q3 cash & investments USD 246.3 million Q3 adjusted EBITDA USD 49.4 million vs. IBES estimate USD 46.5 million
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees